Price Crosses Moving Average
|Bid||41.20 x 800|
|Ask||65.51 x 800|
|Day's Range||54.54 - 58.75|
|52 Week Range||42.00 - 70.00|
|Beta (5Y Monthly)||1.01|
|PE Ratio (TTM)||17.53|
|Earnings Date||May 07, 2020 - May 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced that its Board of Directors appointed Mike Sherman and Corey Fishman to serve as Independent Directors, effective immediately. Mike Sherman and Corey Fishman will both join the Board's Audit Committee, with Mr. Sherman serving as an "audit committee financial expert." Corey Fishman will also join the Intellectual Property Committee.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today announced that the Board of Directors has appointed Joseph Truitt as interim Chief Executive Officer. He will also serve on the Company's Board of Directors. Mr. Truitt succeeds J. Kevin Buchi, who served as CEO since October 2019, and has departed the company.
BioSpecifics (BSTC) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Unfortunately for some shareholders, the BioSpecifics Technologies (NASDAQ:BSTC) share price has dived 32% in the last...
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in North America, today announced its financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate update.
If you own shares in BioSpecifics Technologies Corp. (NASDAQ:BSTC) then it's worth thinking about how it contributes...
BioSpecifics Technologies (BSTC) is a biopharmaceutical company. It is best known as the originator of collagenase-based therapies currently used to treat twelve clinical indications, explains Douglas Gerlach, editor of SmallCap Informer.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Today we will run through one way of estimating the intrinsic value of BioSpecifics Technologies Corp. (NASDAQ:BSTC...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 26% in 2019 (through November 22nd). Conversely, hedge […]
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll look at...
BioSpecifics (BSTC) delivered earnings and revenue surprises of 13.33% and 6.57%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- 15% year-over-year increase in royalty revenues for XIAFLEX® - BLA filing of XIAFLEX® for treatment of cellulite submitted to FDA in September 2019 LYNBROOK, N.Y. , Nov. 8, 2019 /PRNewswire/ -- BioSpecifics ...
BioSpecifics (BSTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]